Protein-Based Nanocarriers and Nanotherapeutics for Infection and Inflammation

Abstract

Infectious and inflammatory diseases are one of the leading causes of death globally.The status quo has become more prominent with the onset of Covid-19 pandemic. In order to combat these potential crises, proteins have been proven as highly efficacious drugs, drug targets and biomarkers. On the other hand, advancements in nanotechnology have aided efficient and sustained drug delivery due to their nano-dimension-acquired advantages.Combining both the strategies together, the protein nanoplatforms are equipped with the advantageous intrinsic properties of proteins as well as nanoformulations, eloquently changing the field of nanomedicine. Proteins can act as carriers, therapeutics, diagnostics and theranostic in their nanoform as fusion proteins or as composites with other organic/inorganic materials. Protein-based nanoplatforms have been extensively explored in order to target the major infectious and inflammatory diseases of clinical concern. The current review comprehensively deliberated proteins as nanocarriers for drugs and nanotherapeutics for inflammatory and infectious agents with special emphasis on cancer and viral diseases.Plethora of proteins from diverse organisms have aided in the synthesis of protein based nanoformulations. The current study specifically presented the proteins of human and pathogenic origin, to dwell upon the field of protein nanotechnology emphasizing on their pharmacological advantages. Further, the successful clinical translation and current bottlenecks of the protein-based nanoformulations associated with infection-inflammation paradigm has also been discussed comprehensively.

Preparation of dual active site ionic liquids and their application in the catalytic synthesis of poly(isosorbide carbonates)

“…Based on the experimental data, the phenomena and related literature reports, 40,41 the reaction mechanism of this ester exchange polycondensation reaction catalyzed by dual active site ionic liquid catalysts was revealed and explored as shown in Fig. 14 (catalyst [TEDA-(tetr) 2 ][IM] 2 was used as an example).…”

Special Section on Nanotechnology-Based Delivery Strategies for Protein and Peptide Therapeutics—Editorial

“…The paper sheds light on the use of inorganic systems, polymeric and lipidic systems, polymer conjugates, and noncovalent modification strategy for delivery of pramlintide alone as well as when coformulated with insulin (Kommera et al, 2023). The last paper of the session, by Nagar et al (2023), focuses on the huge library of promising proteinbased nanocarriers and nanotherapeutics explored for infectious and inflammatory ailments, with particular emphasis on proteins nanoparticles of human and pathogenic origin, with reference to their advantages, pharmacokinetic parameters, and the current bottlenecks in the development of protein-based nanotherapeutic interventions (Nagar et al, 2023).…”